Foghorn Therapeutics Inc. has announced promising preclinical data for its selective SMARCA2 inhibitor, FHD-909, which demonstrates potential for combination therapy with an anti-PD-1 antibody in treating SMARCA4-mutant lung cancer. This development, to be presented at the upcoming 2026 AACR Annual Meeting, highlights the strategic collaboration with Eli Lilly, positioning FHD-909 as a pioneering candidate in a niche but critical area of oncology.

The significance of this research lies in its ability to address cancers with genetic dependencies that are currently underserved by existing therapies. The data presented will underscore not only the efficacy of FHD-909 in preclinical models but also its potential to enhance the therapeutic landscape for patients with SMARCA4 mutations. Additionally, Foghorn will showcase advancements in its other programs targeting CBP, EP300, and ARID1B degradation, further illustrating the company’s commitment to innovating within the chromatin regulatory system to improve treatment outcomes in difficult-to-treat malignancies.

The implications of these findings are substantial for the field of cancer therapeutics. By validating the concept of targeted protein degradation in specific genetic contexts, this research could shift current paradigms in drug development timelines, particularly for precision oncology. The focus on chromatin regulatory proteins opens avenues for developing more effective, tailored therapies, potentially accelerating the transition from preclinical success to clinical application. This approach may redefine treatment strategies for a range of cancers characterized by complex genetic alterations, ultimately enhancing patient healthspan and longevity.

Source: globenewswire.com